DOCSLIB.ORG

Guinea Research Perspectives on Ebola Outbreak

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guinea Research Perspectives on Ebola Outbreak RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE 22nd Canadian Conference on Global Health Capacity Building for Global Health: Research & Pratice Hotel Bonaventure, Montreal, 6-7 November 2015 Guinea Research Perspectives on Ebola Outbreak Mandy Kader KONDE, MD, MPH, PHD Department of Public Health, University of Conakry Chairman Guinea Ebola Research Commission Executive Director Center of Research on Diseases (CEFORPAG) COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE Outline • Background • Main Strategies for Ebola Outbreak Control • R & D Organizational Structure • Research Priorities & Preliminary Findings • Main Lessons learnt • Perspectives COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE Background • Ebola Outbreak in West Africa unprecedented magnitude, new Disease for Communities & Entiere Country • High toll of death among frontline workers • Ecosystem of forest region where people are more & more agressive • Intense migrations / movement accross West Africa Vs Central Africa • Most affected countries, are post-conflict (Sierra Leone, Liberia, Guinea), weak health system • lack of confidence in Public service delivery, poverty • Perception/Acceptance of the Disease & • Negative Impact of Mass media and communication (No drug, No Vaccine, CFR high) COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE Update on Guinea Ebola Epidemic location 30 Dec 2013 – 03 Nov 2015 COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE Main Strategies for Outbreak Control • Case Management (MoH/MSF/WHO) – starting with 2 isolation Centers (Gueckedou, Conakry) to > 8 ETU • Surveillance (MoH/WHO/CDC, PLAN-Guinea, Save the Children) • Contact tracing (MoH/WHO/CDC) • Lab support (Institut Pasteur, UE Mobile Lab, Kaplan, Canadian Mobile Lab, ) • Safe Burial intervention (Croix Rouge) • Communication (MoH/Unicef) • Prevention & Infection Control (MoH/WHO) COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE Guinea Ebola Epidemic Curve & Clinical Trial 30 Dec 2013- 06 Nov 2015 180 Favipiravir Study confirmés (n=3351) 160 probables (n=453) Ring Vaccination Trial 140 23 March 2015 suspects (n=1) 120 Interferon Study 100 Convalescent Plasma 80 Nombre deNombrecas 60 LAB+ 40 21 March 20 0 1_14 3_14 5_14 7_14 9_14 1_15 3_15 5_15 7_15 9_15 29_14 47_14 13_15 31_15 11_14 13_14 15_14 17_14 19_14 21_14 23_14 25_14 27_14 31_14 33_14 35_14 37_14 39_14 41_14 43_14 45_14 49_14 51_14 11_15 15_15 17_15 19_15 21_15 23_15 25_15 27_15 29_15 33_15 35_15 37_15 39_15 41_15 43_15 45_15 Semaine de début des signes Epidemic Curve with 6 Waves COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE HCW Infection during Ebola Outbreak 90 Guinea, 30/12/2013 – 09/06/2015 79 80 70 60 50 Nb Confirmés = 187 40 36 Nb Probable = 15 Décès Confirmés=94 30 Décès Probable= 15 19 20 18 13 14 11 12 12 11 9 9 10 7 8 4 4 5 5 2 2 2 3 3 2 2 3 3 2 2 1 1 1 1 0 0 1 1 1 1 1 0 confirmes_probables deces COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE Update as of 06 November 2015 Total Cases Total Death % Total Confirmed cases 3 351 2 083 62% Total Probables cases 453 453 Total cas suspected 02 0 All Total cases (confirmed, 3 806 2 536 67% probables et suspected ) Survivors (estimated) 1 270 Health Care Workers 211 115 55% COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE R & D Organizational Structure • Ebola Research Commission (CRE) (April 14) – Coordination of research activities – Research capacity building • Ethical committee (CNERS) – Assessment of compliance of the research to international ethical standard • National Regulatory Authority (NRA) – Lot authorization importation – Pharmaco vigilance • NIH Collaboration Committee – Established June 2015 COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE Research Priorities – Therapies, Vaccines, Diagnostics & others trial – Social aspects (Perception & community engagement, behavioral changes) – Research training for local investigators (GCP, virology, clinical research, anthropology and social science…) – Post-epidemic management (survivors, health system recovery…) – Environmental & Ecological study COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE Clinical Trial (CT) - Therapies Product/Spon Trial Description Design Location Enrolled/ Goal sor & Phase Favipiravir Safety & Efficacy Non random, Open- Gueckedou, 126/225 (JIKI) Phase 2 label, Single arm, Nzerekore, Prelimirary INSERM-F Historical Control Macenta, Coyah, data presented Forecariah Seattle, Oct 14 Convalescent Safety & Efficacy Non random, Conakry 102/130 Plasma (CP) Phase 2/3 (based on CP Consortium availability) Open- Ebloa Tx label, 2 arms, Control is SOC Interferon Safety & Efficacy Non random, Open- Coyah 9/30 Beta 1 a (IFN) Phase 1/2 label, Single arm, University of historical Control Toronto Favipiravir – Safety & Efficacy Non random, Open- Coyah, 12/ Zmap (JIKI- Phase 2 label, 2 arms, Forecariah Map) Control is SOC Jiki INSERM & NIH COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE CT - Vaccine & Other Trials Product/ Sponsor Trial Design Location Enrolled/ Description & Goal Phase rVSV-ZEBOV Efficacy & Safety Cluster-randomized, open Basse > 7 651 Consortium (WHO, – Ring label vaccines Guinea Preliminary Norway, MSF, Canada, Vaccination (Vaccination of contacts/ data Welcomme Trust, etc) Phase 3 Contact of contacts) of published confirmed cases, Lancet Immediate Vs Delayed vaccination (21 days) rVSV-ZEBOV Safety & Non-Random, open label, Basse 1 200 Consortium (WHO, Immunogenicity Single arm receiving Guinea Norway, MSF, Canada, – Frontline vaccine Welcome Trust) workers POSTEBOGUI Ebola Survivor 22 months Follow up Conakry, 300 INSERM study cohorte of survivors Macenta (socio-anthropology, biochemical, immuno, virological, Ophtamo, COORDINATION NATIONALE DE LUTTENeuro CONTRE LA MALADIE À VIRUS EBOLA Survivors Study Ebola Survivor Immunology Gueckedou 90 Public Health study Coyah 120 England, CEFORPAG RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE Lancet. 2015 Aug 3. pii: S0140-6736(15)61117-5. doi: 10.1016/S0140-6736(15)61117-5. COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE 14 COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE All vaccinated adults assigned to immediate vaccination versus all eligible individuals assigned to delayed vaccination †Four cases were vaccinated and developed symptoms on day 0, 2, 6, 6 15 COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE CT-Diagnostic Products Product Manufacturer/ Technology Platform Location Sponsor Samples BioThreat-E BioFire Defense Multiplex rRT-PCR Film Array Macenta IPP Blood, Urine Xpert Ebola Cepheid rRT-PCR GeneXpert Conakry MSF Venous Blood Oraquick OraSure Ebola Rapid Conakry Technolies Antigen Test (PN CDC-Atlanta 3001-2812) Blood, Swab Ebotest 2 Institut Pasteur Rapid test RPA Macenta Blood EBOV-RT- Institut Pasteur 928 post-mortem TR-RPA Conakry RPA Dakar swabs, COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE Case Management & Research Coyah & Nongo ETU (Favipiravir & Visit Eleanor Fish University Toronto, Nongo Interferon are tested) ETU (Co-PI Interferon Trial ) COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE Secure Burial Process by Red Cross COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE Ring Vaccination Trial with rVSV vaccine COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE Sub Regional Ebola Research Partnership Sierra Guinea Liberia Leone Research Collaboration: 1+1+1=1 COORDINATION NATIONALE DE LUTTE CONTRE LA MALADIE À VIRUS EBOLA RÉPUBLIQUE LA GUINÉE Travail-Justice-Solidarité MINISTÈRE DE LA SANTE Main Lessons learnt • Need for long term collaboration on Institutional basis • Real capacity building (strenghten Human ressources & lab infrastructure) rather than just publications or colonial consideration • Influence Politic & Science, Need for better coordination (complementary vs duplication/ competition) • Lack of national leadership & Ownership • Orientation of funds raised by partners • Need for a regional framework for multicenter studies on therapies, vaccines & Diagnostic test with neighboring’s countries • How Research on disease control could better prepare
Load more

Recommended publications
  • Cytokines MONTRÉAL 2008
    Cytokines MONTRÉAL 2008 Translating Science into Health: Cytokines in Cancer, Infl ammation and Infectious Diseases 7th Joint Conference of the International Cytokine Society and the International Society for Interferon and Cytokine Research Photo: Tourisme Montréal Photo: Tourisme October 12-16, 2008 Fairmont Queen Elizabeth Hotel Montreal Quebec CANADA Cytokines Montreal 2008 1 PROGRAM From cell separation to molecular analysis The Gold Standard in Cell Isolation • Separation of functional, cytokine-secreting cells • Virtually any cell type from any species • Superior viability, purity and recovery Cytokines and Growth Factors • New, broad portfolio: human - mouse - rat • Excellent purity and activity • Optimized for cell culture applications MACSmolecular Tools for Molecular Analysis • Tools for signal transduction • State of the art microRNA analysis • Comprehensive gene expression profiling Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. Miltenyi Biotec Inc. Phone 800 FOR MACS www.miltenyibiotec.com 12740 Earhart Avenue +1 530 888 8871 [email protected] Auburn CA 95602, USA Fax +1 530 888 8925 2 Cytokines Montreal 2008 ContentsWelcome to Montreal ..................................................................................... 4-5 Sponsors and Exhibitors ................................................................................... 6 Conference Venue ...........................................................................................
    [Show full text]
  • Beyond Vaccines: Promising Therapeutics for COVID-19 and Emerging Viruses
    Research Canada speaks to Dr. Eleanor Fish, a scientific advisor to Canada’s COVID- 19 Therapeutics Task Force Beyond Vaccines: Promising Therapeutics for COVID-19 and Emerging Viruses The federal government’s COVID-19 Therapeutics Task Force provides advice on the best and most promising treatments for COVID-19 procurement, whether these are still in development and merit support, including via applications to the federal Strategic Innovation Fund, or are existing medications. The Task Force also makes recommendations on therapies developed for a different use that may have an application to COVID-19. Dr. Eleanor Fish is among 11 science advisors to the Therapeutics Task Force. A Professor of Immunology at the University of Toronto and a Senior Scientist at University Health Network, she investigates the behaviour of cytokines, which play a role in cell-to-cell communication during the body’s immune response. In a recent Research Canada interview with Ms. Deborah Gordon-El- Bihbety, President and CEO, Dr. Fish talked about the critical place of therapeutics in the battle against COVID-19, and their important role in preparing for the diseases and epidemics to come. "Vaccines are a very important tool in our toolbox against COVID-19, but they are not a complete solution." - Dr. Eleanor Fish 1 RESEARCH CANADA: Canada’s vaccination campaign is under way, and we’ve been told that all Canadians who want a vaccine will have it by next fall. What role do therapeutics play, separate from vaccines, in the fight against COVID-19? DR. ELEANOR FISH: Vaccines are a very important tool in our toolbox against COVID-19, but they are not a complete solution.
    [Show full text]
  • ISICR Vol. 15.1
    ISICR Officers President Eleanor Fish President-elect INTERNATIONAL SOCIETY FOR Leonidas Platanias INTERFERON AND CYTOKINE RESEARCH Secretary April 2008 Tom Hamilton Volume 15, No. 1 Treasurer Bob Friedman Executive Director A Message from the new ISICR Cliff Brownstein President, Eleanor Fish It is with gratitude and humility that I assume the Future ISICR Meetings responsibilities of incoming President of the ISICR. I am honored to have been elected by my peers and am fortunate to have in place a Board of 2008 Meeting Directors and Committee members that are as Joint ISICR/ICS committed to strengthening our Society as I am. In Montreal, Canada recent months, to ensure that our Society reflects Oct. 12-16 the scientific activities of junior investigators, as positions have www.cytokines2008.org become vacant on the various ISICR Committees, in consultation 2009 Meeting with the Committee Chairs I have made best efforts to invite the par- Joint ISICR/ICS/SLB ticipation of younger investigators who share our vision of a strong, Lisbon, Portugal international, collegial Society. I invite members to participate in your Society - just contact me to let me know of your interest. 2010 Meeting Joint ISICR/ICS Within recent years we have seen a revival of interest in the Chicago, Illinois pleiotropic activities of interferons, touching on many different bio- logical disciplines. Moreover, the role of cytokines and how they ISICR WWW Site inform us of biological processes in normal and diseased states is an www.ISICR.org ever expanding field. I would like to focus my tenure as President on a number of key areas: ISICR Business Office O Communication.
    [Show full text]
  • Dec 08 News Vol 15 No 3 Final.Qxp
    ISICR Officers President Eleanor Fish President-elect Leonidas Platanias Secretary Tom Hamilton December 2008 - Volume 15, No. 3 Treasurer Bob Friedman Executive Director One on one: An Interview with Cliff Brownstein Giorgio Trinchieri, Recipient of the 2008 Milstein Award Future ISICR Meetings Thomas Tan 2009 Meeting Giorgio Trinchieri received his medical degree Joint ISICR/ICS/SLB from the University of Torino, Italy, in 1973. He Lisbon, Portugal was a member of the Basel Institute for Immunology (Basel, Switzerland) and an investi- 2010 Meeting gator at the Swiss Institute for Experimental Joint ISICR/ICS Cancer Research (Epalanges sur Lausanne, Chicago, Illinois Switzerland). From 1979 to 1999 he was at Wistar Institute in Philadelphia and became Hilary Koprowski Professor and Chairman of the Immunology Program; he ISICR WWW Site was also Wistar Professor of Medicine at the University of www.ISICR.org Pennsylvania. He then served as director of the Schering Plough Laboratory for Immunological Research in Dardilly, France, and an ISICR Business Office NIH Fogarty Scholar at the Laboratory for Parasitic Diseases, [email protected] NIAID, before becoming director of the Cancer and Inflammation TEL: 301-634-7250 Program (CIP) and Chief of the Laboratory of Experimental FAX: 301-634-7420 Immunology at NCI in August 2006. As CIP director, he oversees the operations of two major NCI intramural laboratories, the Laboratory ISICR Newsletter Editors of Experimental Immunology and the Laboratory of Molecular Howard Young Immunoregulation. These two laboratories constitute the major [email protected] immunologic component of the inflammation and cancer initiative, Fax: 301-846-1673 which spans the NCI's campuses in Frederick and Bethesda and seeks Hannah Nguyen to partner NCI's expertise in inflammation and immunology with its cutting-edge cancer etiology and carcinogenesis program.
    [Show full text]
  • CMAJ WHO Enters New Terrain in Ebola Research
    CMAJ News WHO enters new terrain in Ebola research he meeting on unproven inter- ventions for Ebola at the World T Health Organization on Sept. 4 and 5 takes the global agency into “absolutely uncharted territory,” says WHO spokesperson, Dr. Margaret Harris. “We’re actually often criticized for being incredibly slow about saying, ‘Do this over that’, because we demand enormous levels of evidence,” she says. But for Ebola virus disease, there are no approved therapies, so WHO is attempting to move investigational interventions forward, including medi- cations, vaccines and so-called conva- lescent serum, made from the blood of survivors. The Sept. 4 meeting, aimed at guid- ing research in the midst of the out- NikiLitov/iStock/Thinkstock break, marks a sharp turn for WHO, In the absence of approved therapies for patients diagnosed with Ebola, WHO is taking where research efforts are viewed as the unprecedented step of attempting to move research forward. fragmented. About five years ago, WHO eliminated its office of research break at 78%, and in late August the three control animals died. Five of the strategy; the department leading the disease spread to another country — seven people treated with ZMapp have Ebola research effort, known as Senegal — and another city — Port survived, but it is unclear if the medica- Knowledge, Ethics and Research, was Harcourt, Nigeria, the hub of Nigeria’s tion helped them to recover and it will only formed at the end of 2013. But the oil and gas industry, where Canadian be months before there is more ZMapp Ebola crisis forced a change.
    [Show full text]
  • Keynote Speakers
    Keynote Speakers Dr. Katie Flanagan, BA(Hons) MBBS DTM&H MA PhD CCST FRCP FRACP, leads the Infectious Diseases Service at Launceston General Hospital in Tasmania, and is a clinical Associate Professor at the University of Tasmania, Australia. She obtained a degree in Physiological Sciences from Oxford University, followed by her MBBS from the University of London. She is a UK and Australia accredited Infectious Diseases Physician. Katie obtained her PhD in malaria immunology based at Oxford University. She was previously Head of Infant Immunology Research at the MRC Laboratories in The Gambia from 2005-11. Dr. Thumbi Ndung’u, BVM, PhD, is the Scientific Director of the HIV Pathogenesis Programme at the University of KwaZulu Natal in South Africa. He is a virologist with a PhD from Harvard University, Boston, USA. His main research interests are in host-virus interactions and immune responses in HIV-1 infection. He is also interested in the development of biomedical interventions that can be used in resource-limited settings to prevent or treat HIV/AIDS. He is an Associate Professor in HIV/AIDS Research at the the Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal. He holds the South African Department of Science and Technology/National Research Foundation (DST/NRF) Research Chair in Systems Biology of HIV/AIDS. Dr. Josef Penninger BA, MD, PhD, is Scientific Director of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria. He is Professor in the Departments of Immunology and Medical Biophysics at the University of Toronto, Canada, Professor of Genetics, University of Vienna, Austria, Honorary Professor of Peking Union Medical College/Chinese Academy of Medical Sciences, Beijing, China, Affiliate Scientist, Keenan Research Centre, Li Ka Shing Knowledge Institute of St.
    [Show full text]
  • The Dynamic Changes in Cytokine Responses in COVID-19
    meeting report SARS-COV-2 The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge “The role of cytokines in COVID-19” online symposium was presented on 18 June 2020 by the NIH/FDA Immunology and Cytokine Interest Groups and was purposed to discuss our rapidly changing understanding of COVID-19-related cytokine responses in diferent stages of infection, including the etiologies, downstream consequences and possible mitigation strategies. The recording is available at https://nci.rev.vbrick.com/ sharevideo/03106730-66cc-47ba-870b-f6e6274a998a. he symposium was opened by address that underscored the broad variety serum cytokine concentrations with disease Anthony Fauci, Director of the of clinical presentations of COVID-19, outcome. Her data showed that IL-6, IL-8 TNational Institute of Allergy and thus highlighting the central role of the and TNF, and to a lesser extent, IL-1β, were Infectious Diseases at the US National immune response in this disease. She also elevated at the time of hospitalization, and Institutes of Health (NIAID, NIH), and remarked on the apparent geographic their concentrations correlated with disease Janet Woodcock, Director of the Center clusters of disease manifestations and the outcome and mortality, even after correcting of Drug Evaluation and Research, Food need to better understand possible factors for age, ethnicity, race and comorbidities, and Drug Administration (CDER, FDA) in host–pathogen interactions beyond those suggesting that they could be used to and currently leading the therapeutics health conditions already identified, such identify patients at risk of severe disease2. component of Operation Warp Speed.
    [Show full text]
  • December 2012
    Department of Immunology Newsletter image provided by Michael Corrin VOL I – ISSUE 4 December 2012 Message from the Chair, UPCOMING SEMINARS Dr. Juan Carlos Zúñiga-Pflücker EASTON SEMINARS – Another year, another spectacular Immunology Holiday Party for January 2013 which we have Alessandra Ferzoco, Elisa Porfilio and many IGSA Room 2172 MSB at 11:10 a.m. members to thank. Jennifer Gommerman’s Mayan inspired January 14, 2013 apocalyptic monologue was terrific, and terrifying if we really had Richard M. Ransohoff, MD to choose whom to save. For those that could not make it, I am “Monocytes and microglia: Where they sorry, you missed a wonderful evening, but here is a recap of some come from and what they do.” (Host: Dr. Eleanor Fish) key items: the Richard Miller award was given to Janet Markle (Danska lab) and the Bernhard Cinader award by was given to January 21, 2013 Peter Chen (Carlyle lab); the Examiner of the Year award went to Jorge Kalil, MD, PhD “From molecular immunopathogenesis Michele Anderson, with Alberto Martin as a close runner-up. Our to the development of a vaccine to avoid department’s long-running holiday party DJ, Ernie West, was a post infectious human autoimmune recognized for his many years of service, and James Carlyle won disease.” (Host: Dr. Michelle Letarte) the newly minted “Lord of the dance” gold record award. The centerpiece competition winners were from the Kelly MacDonald January 28, 2013 lab, and the Zúñiga-Pflücker lab as runner-ups. The new fashion- Jeremy Mogridge, PhD show competition award was won by Catherine Schrankel (Rast “Detection of danger by the Nlrp1b inflammasome.” lab).
    [Show full text]
  • Murine Hepatitis Virus Strain 1 As a Model for Severe Acute Respiratory Distress Syndrome (Sars)
    MURINE HEPATITIS VIRUS STRAIN 1 AS A MODEL FOR SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME (SARS) Nadine DeAlbuquerque, Ehtesham Baig, Max Xuezhong, Itay Shalev, M. James Phillips, Marlena Habal, Julian Leibowitz, Ian McGilvray, Jagdish Butany, Eleanor Fish, and Gary Levy* 1. INTRODUCTION Severe acute respiratory syndrome (SARS) is a novel infectious disorder that was first diagnosed in China in November 2002.1,2 SARS was documented in approximately 8,000 persons globally with more than 700 deaths. In Canada, there were 375 probable and suspect cases between March and July 2003 with 44 deaths, reflecting a mortality rate of 11%. Spread of SARS was shown to be by airborne droplets and results in acute pulmonary inflammation and epithelial damage.3 It has now been determined that a novel coronavirus, SARS-CoV, is the etiologic agent in SARS. Based on phylogenetic sequence analysis, it best fits within group 2 coronaviruses, which include the mouse hepatitis viruses (MHV).4,5 As for most infections, SARS varies considerably in terms of its clinical severity. This variation is almost certainly due to population-based diversity in the genes controlling the immune response. Clearance of mouse hepatitis virus coincides with a robust innate immune response, including increased numbers of CD8 T cells. Disease and death do not correlate with high viral titers, and it has been suggested that disease reflects alteration in host innate immune response. Furthermore, host production and response to type 1 interferons (IFN) is a key determinant of outcome in MHV-infected mice.6 However, IFNs and other cytokines regulate in a coordinate manner both inflammation and the Th1/Th2 character of the specific immune response.
    [Show full text]
  • Therapeutic Effectiveness of Interferon-Alpha 2B Against COVID-19: the Cuban Experience
    medRxiv preprint doi: https://doi.org/10.1101/2020.05.29.20109199; this version posted June 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience Pereda R1, González D1, Rivero HB1, Rivero JC1, Pérez A1, López LR1, Mezquia N1, Venegas R1, Betancourt JR2, Domínguez RE3. 1 Medical college of Havana. Havana city, Cuba. 2 Medical college of Villa Clara. Santa Clara city, Cuba. 3 Medical college of Camaguey. Camagüey city, Cuba. Correspondence to: Ricardo Pereda González Cuban Ministry of Public Health 202, 23 Street, Vedado, Plaza de la Revolución. Havana, Cuba [email protected] key words: interferon, COVID-19, SARS-Cov-2 NOTE: This preprint reports new research that has not been certified1 by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.05.29.20109199; this version posted June 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. ABSTRACT Background Effective therapies are needed to control the SARS-Cov-2 infection pandemic and reduce mortality associated with COVID-19. Several clinical studies have provided evidence for the antiviral effects of type I interferons (IFNs) in patients with respiratory coronaviruses.
    [Show full text]
  • What a COVID-19 Vaccine May Mean for Ageing Adults
    What a COVID-19 Vaccine may Mean for Ageing Adults Interview with Wayne Ko˛, Ph.D. President and CEO Human Vaccines Project Wayne Ko˛ is the founding President and CEO of the Human Vaccines Project (HVP). He has decades of experience in vaccine development and may also soon be a trial volunteer, having signed up to participate in future COVID-19 vaccine studies. Ko˛ is also an Adjunct Professor of Epidemiology at the Harvard T.H. Chan School of Public Health (HSPH), which is partnering with the HVP to decipher what e˛ective immunity is in ageing adults. HVP Editor Kristen Jill Abboud recently discussed the state of COVID-19 vaccine research with Ko˛ and asked him about the priorities for evaluating and deploying eventual vaccines in various populations, including the elderly. An edited version of the conversation appears below. What are the most critical unanswered questions about immunity to this novel coronavirus? The major unanswered question is: what causes the wide breadth of pathogenesis we see with this virus in di˛erent age groups and in di˛erent populations? What is at the root of that? Within that, there are speciÛc questions about pathogenesis within the elderly. We’re learning more and more that people have a chronological age, but they also have a biological age, and most likely also an immune age. We have the capacity now with the tools at our disposal—tools of systems biology, all of the ‘omics’ assays, and advances in artiÛcial intelligence and machine learning—to really understand this immune age in ways we couldn’t possibly have just a few years ago.
    [Show full text]
  • Kate Fitzgerald
    In This Issue: 2019 Young Investigator Awardees pgs. 3-8 Italian COVID-19 Storms pg. 11 In Memorium pgs. 12-15 New Member Mini-Bios pgs. 17-19 Spotlight: Women in Science pgs. 21-23 Cytokines 2020 pgs. 24-27 Si g n THE INTERNATIONALa CYTOKINEl & INTERFERONs SOCIETY+­­­ NEWSLETTER APRIL 2020 I VOLUME 8 I NO. 1 A NOTE FROM THE ICIS PRESIDENT Kate Fitzgerald I write this note as all of us reach a new norm of working “remotely”. I want to extend my sincere appreciation to all members of the ICIS community around the globe who have stepped up to meet the unique and unforeseen challenges of this time. The precautions that have been implemented at all of our institutions and companies, in accordance with local and national public health guidance, will no doubt help mitigate the spread of COVID-19. We should remain firmly committed to physical distancing to make us all safer. We stand with our Italian, Spanish and New York colleagues in particular, who are facing very difficult times right now and hope things will improve there soon. It’s hard to understate the importance of the scientific enterprise and the work we as cytokine and interferon biologists do in light of the COVID-19 pandemic. Our past and current efforts to understand the host response to viruses and other pathogens and the importance of IFN and cytokines in controlling infection and the immune response to vaccines could not be more important than it is now. Understanding cytokine and interferon biology is fundamental to human health and disease.
    [Show full text]